Systemic and targeted therapy for advanced colon cancer
Authors:
- Weijing SunWSWeijing Sun
- John P LynchJLJohn P Lynch
- 1 February 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Gastroenterology & Hepatology
- Vol. 2 (1) , 135-149
Abstract
Colorectal cancer (CRC) is the third most common malignancy and the second most common cause of cancer-related death in the USA. Prognosis is best when the disease is detected early; however, nearly two-thirds of newly diagnosed cases of CRC have lymph node involvement or metastatic disease. For years, 5-fluorouracil (FU)-based regimens represented the only viable treatment option for patients with metastatic CRC. However, in recent years several newer agents have been added to the treatment arsenal for this disease. These agents include oxaliplatin, irinotecan and newer monoclonal antibodies targeting the epidermal growth factor receptor (cetuximab and panitumumab) and VEGF (bevacizumab). This review aims to discuss current systemic and targeted therapies for metastatic colon cancer with a focus on mechanism of action, indications, toxicity and efficacy.Keywords
This publication has 95 references indexed in Scilit:
- Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid CancersJournal of Clinical Oncology, 2007
- Epidermal Growth Factor Receptor Signaling Is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic CarcinogenesisCancer Research, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Targeting the Expression of Platelet-Derived Growth Factor Receptor by Reactive Stroma Inhibits Growth and Metastasis of Human Colon CarcinomaThe American Journal of Pathology, 2006
- Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative SurgeryAnnals of Surgical Oncology, 2006
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- The Hallmarks of CancerCell, 2000
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panelBiochemical Pharmacology, 1996
- Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.BMJ, 1993